Skip Menu

Stroke Clinical Trials at OhioHealth

Pioneering Stroke Treatments and Technologies

WE are a nationwide leader in research through our active participation in stroke clinical trials.

Because of the high volume of stroke patients we treat, OhioHealth Neuroscience Center at Riverside Methodist Hospital is able to pioneer leading-edge treatments and technologies through active participation in clinical trials. 

Stroke Clinical Trials at OhioHealth

Below are the stroke clinical trials in which we’re currently actively involved: 


Atrial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

The purpose of this trial is to test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.

Learn more at


Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

The purpose of this study is to validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes.

Learn more at


Embotrap Extraction & Clot Evaluation & Lesion Evaluation for NeuroThrombectomy

The objective of this study is to assess the efficacy of the EmboTrap® Revascularization Device in a real-world setting, as well as to explore correlations between patient comorbidities, clot characteristics, revascularization rates, and clinical outcomes.

Learn More at


Early Minimally-invasive Removal of ICH

The purpose of this trial is to provide clinical evidence of functional improvement, safety, and economic benefit when comparing intracerebral hemorrhage (ICH) evacuation surgery to medical treatment.

Learn more at


A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects with Acute Ischemic Stroke Undergoing Endovascular Thrombectomy (ESCAPE-NA1 Trial)

The purpose of this trial is to determine the efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation selected for rapid endovascular revascularization.

Learn more at


Impact of Fever Prevention in Brain Injured Patients (INTREPID)

The purpose of this study is to assess fever burden and the impact on outcomes of fever prevention using the Arctic Sun 5000 Temperature Management System as compared to standard fever care in brain-injured patients.

Learn more at


Ruptured Aneurysms Treated with Hydrogel Coils

The purpose of this study is to determine the safety and occlusion rates when hydrogel coils are used in the treatment of ruptured intracranial aneurysms.

Learn more at


Treatment with Intent to Generate Endovascular Reperfusion

The objective of the TIGER Study is to evaluate the safety and effectiveness of the Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke due to a large vessel occlusion (LVO).

Learn more at


Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) Protocol

A set of two multicenter randomized trials that run in parallel – CEA in addition to intensive medical management (IMM) vs. intensive medical management alone OR CAS + IMM vs. IMM alone.

Learn more at


CREST 2 Registry (C2R)

A companion study to accompany CREST-2, this registry is for expansion of Medicare coverage for CAS to include procedures performed as part of C2R on symptomatic and asymptomatic patients beyond those categories covered under the 2005 CMS decision. Patients must either be excluded from or decline randomized trial CREST-2. 

Learn more at


AMPLATZERTM PFO Occluder Post Approval Study

The purpose of this study is to confirm the safety and effectiveness of the AMPLATZERTM PFO Occluder in the post approval setting. The AMPLATZERTM PFO Occluder is indicated for percutaneous, transcatheter closure of a PFO to reduce the risk of recurrent ischemic stroke in patients, who have had a cryptogenic stroke due to presumed paradoxical embolism.

 Learn more at